Cargando…

Effect of Belimumab on Preventing de novo Renal Lupus Flares

INTRODUCTION: Belimumab was recently approved for treating lupus nephritis (LN), yet de novo LN cases during belimumab treatment given for nonrenal causes have been reported. Identification of reliable signals of impending flare is imperative. METHODS: We evaluated belimumab efficacy in preventing d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parodis, Ioannis, Lindblom, Julius, Cetrez, Nursen, Palazzo, Leonardo, Ala, Henri, Houssiau, Frédéric A., Sjöwall, Christopher, Rovin, Brad H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496079/ https://www.ncbi.nlm.nih.gov/pubmed/37705915 http://dx.doi.org/10.1016/j.ekir.2023.06.021

Ejemplares similares

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020)

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature
por: Palazzo, Leonardo, et al.
Publicado: (2022)

Prediction of prognosis and renal outcome in lupus nephritis
por: Parodis, Ioannis, et al.
Publicado: (2020)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

Letter in reply: Crusted scabies mimicking a lupus flare after rituximab and belimumab
por: Androsov, Grigoriy, et al.
Publicado: (2021)

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus
por: Sohrabian, Azita, et al.
Publicado: (2019)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade
por: Lindblom, Julius, et al.
Publicado: (2022)

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2022)

Renal flare as a biomarker of incident and progressive chronic kidney disease in patients with lupus nephritis
por: Parikh, S, et al.
Publicado: (2012)

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
por: Parodis, Ioannis, et al.
Publicado: (2020)

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
por: Parodis, Ioannis, et al.
Publicado: (2022)

An update on belimumab for the treatment of lupus
por: Thanou-Stavraki, Aikaterini, et al.
Publicado: (2011)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Belimumab in Systemic Lupus Erythematosus
por: Srivastava, Ankita
Publicado: (2016)

Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus
por: Lokhandwala, Tasneem, et al.
Publicado: (2021)

Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022)

A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial
por: Tamirou, Farah, et al.
Publicado: (2015)

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus
por: Dimelow, Richard, et al.
Publicado: (2020)

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2022)

The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare
por: Toy, Chris R., et al.
Publicado: (2021)

Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial
por: Anders, Hans-Joachim, et al.
Publicado: (2023)

New treatment options for lupus – a focus on belimumab
por: Chiche, Laurent, et al.
Publicado: (2012)

Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab
por: Guzman, Marla, et al.
Publicado: (2020)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

B cell alterations during BAFF inhibition with belimumab in SLE
por: Ramsköld, Daniel, et al.
Publicado: (2018)

Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders
por: Parikh, Samir V, et al.
Publicado: (2015)

Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
por: Borg, Alexander, et al.
Publicado: (2023)

Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2021)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

Belimumab: First targeted biological treatment for systemic lupus erythematosus
por: Dubey, Ashok K., et al.
Publicado: (2011)

Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
por: Frieri, Marianne, et al.
Publicado: (2015)

Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus
por: Plüß, Marlene, et al.
Publicado: (2020)

Belimumab in Lupus Nephritis: A Systematic Review and Meta-Analysis
por: Shrestha, Sanjeev, et al.
Publicado: (2021)

The Role of Belimumab in Systemic Lupus Erythematosis: A Systematic Review
por: Joy, Ashna, et al.
Publicado: (2022)

Urine proteomic insights from the belimumab in lupus nephritis trial
por: Weeding, Emma, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4kdribha5sg3m1kgak0tcv48sr